Literature DB >> 17985312

Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours.

A Kasprzak1, K Olejniczak, W Przybyszewska, M Zabel.   

Abstract

In view of the unclear prognostic and diagnostic role of interleukin 2 (IL-2) and its receptor in human tumours, we examined the cellular expression of IL-2 and of the subunit alpha of its receptor (IL-2Ralpha, CD25) in relation to the proliferative activity of various subtypes of lung tumours. The immunocytochemical ABC technique was applied to archival tissue material of neuroendocrine lung tumours: lung carcinoids, including typical carcinoids (TC), atypical carcinoids (AC) and small-cell lung cancers (SCLC) and squamous cell lung cancers (non-small cell lung cancers, NSCLC). Expression of IL-2 was detected in all types of lung tumours. The highest frequency of IL-2 expression (93%) was noted and the most pronounced semi-quantitatively evaluated expression of IL-2 was detected in AC tumour cells. The expression was more pronounced as compared to neoplastic SCLC (p = 0.01) and NSCLC cells (p = 0.005). The results suggest a negative correlation between IL-2 expression and the proliferative activity of tumour cells (evaluated by expression of Ki-67) in AC. The frequency of detection of IL-2 receptor (IL-Ralpha, CD25) was the highest in NSCLC (94%). Semi-quantitative expression of IL-2R, like that of IL-2, also dominated in the group of atypical lung carcinoids but manifested a significant difference only as compared to typical carcinoids (p = 0.014). Within the groups of tumours studied no correlation could be detected between cellular expressions of IL-2 and IL-2R. Our results demonstrate variable expression of IL-2 and its receptor in various types of lung tumours, but no simple relationship could be detected between tissue expression of the markers and proliferative activity. Appraisal of the diagnostic and/or prognostic significance of the results requires further study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17985312

Source DB:  PubMed          Journal:  Folia Morphol (Warsz)        ISSN: 0015-5659            Impact factor:   1.183


  5 in total

1.  Elevated serum soluble interleukin-2 receptor levels increase malignancy-related risk in patients on chronic hemodialysis.

Authors:  Chen XiaoHong; Shen Bo; Xiang FangFang; Guo Man; Zou JianZhou; Liu ZhongHua; Lv WenLv; Cao XueSen; Ding XiaoQiang; Zhang Boheng
Journal:  Int J Clin Oncol       Date:  2019-06-10       Impact factor: 3.402

2.  Atypical thymic carcinoid manifesting with nephrotic-range proteinuria in a 7-year-old boy.

Authors:  Jolanta Soltysiak; Danuta Ostalska-Nowicka; Katarzyna Zaorska; Karolina Sterzyńska; Katarzyna Derwich; Jacek Zachwieja
Journal:  Pediatr Nephrol       Date:  2017-05-05       Impact factor: 3.714

3.  Prognostic significance of tumor-infiltrating CD8⁺ or CD3⁺ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer.

Authors:  Chuntao Tian; Shixin Lu; Qingxia Fan; Weijie Zhang; Shunchang Jiao; Xiao Zhao; Zhiyong Wu; Liang Sun; Liuxing Wang
Journal:  Chin Med J (Engl)       Date:  2015-01-05       Impact factor: 2.628

4.  Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Authors:  Christian Klein; Inja Waldhauer; Valeria G Nicolini; Anne Freimoser-Grundschober; Tapan Nayak; Danielle J Vugts; Claire Dunn; Marije Bolijn; Jörg Benz; Martine Stihle; Sabine Lang; Michaele Roemmele; Thomas Hofer; Erwin van Puijenbroek; David Wittig; Samuel Moser; Oliver Ast; Peter Brünker; Ingo H Gorr; Sebastian Neumann; Maria Cristina de Vera Mudry; Heather Hinton; Flavio Crameri; Jose Saro; Stefan Evers; Christian Gerdes; Marina Bacac; Guus van Dongen; Ekkehard Moessner; Pablo Umaña
Journal:  Oncoimmunology       Date:  2017-01-11       Impact factor: 8.110

Review 5.  Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer.

Authors:  Arturo Valle-Mendiola; Adriana Gutiérrez-Hoya; María del Carmen Lagunas-Cruz; Benny Weiss-Steider; Isabel Soto-Cruz
Journal:  Mediators Inflamm       Date:  2016-05-12       Impact factor: 4.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.